Results 141 to 150 of about 1,076,058 (285)

Increased Event-Related Potentials and Alpha-, Beta-, and Gamma-Activity Associated with Intentional Actions [PDF]

, 2016
Susanne Karch, Fabian Loy, Daniela Krause, Sandra Schwarz, Jan Kiesewetter, Felix Segmiller, Agnieszka I. Chrobok, Daniel Keeser, Oliver Pogarell   +8 more
openalex   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

ARTEM-IS for ERP: Agreed Reporting Template for EEG Methodology-International Standard for Event-Related Potential Experiments. [PDF]

Psychophysiology
Šoškić A, Ković V, Algermissen J, Fischer NL, Ganis G, Gau R, Mushtaq F, Niso G, Oostenveld R, Pajić D, Pavlov YG, Stekić K, Yang YF, Styles SJ.   +13 more
europepmc   +1 more source

Timing of repetition suppression of event‐related potentials to unattended objects [PDF]

, 2018
Gábor Stefanics, Jakob Heinzle, István Czigler, Elia Valentini, Klaas Ε. Stephan   +4 more
openalex   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Investigating event-related potential (ERP) deviations in clinical high-risk populations for psychosis: a systematic review and meta-analysis. [PDF]

BMC Psychiatry
Wei A, Gao R, Fan M, Luan P, Kong L, He X.   +5 more
europepmc   +1 more source

Event related potential (ERP) as a reliable biometric indicator: A comparative approach

, 2020
Malihe Sabeti, Reza Boostani, Ehsan Moradi   +2 more
openalex   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Acute Exercise Effects on Cognitive Flexibility in Preterm and Full-Term Children: An Event-Related Potential Study. [PDF]

Int J Med Sci
Chen FT, Hsiao PC, Hillman CH, Feng SH, Chu CH, Chang YK.   +5 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source